Article

# Establishing AI in MedTech: A Strategic Blueprint for QA/RA Leaders

As MedTech continues its digital evolution, the integration of Artificial Intelligence (AI) — particularly within Quality Management Systems (QMS) and Regulatory Information Management (RIM) — is no longer a future ambition but a present imperative. For Quality Assurance and Regulatory Affairs (QA/RA) professionals, the challenge is not just adopting AI, but laying the groundwork to ensure its success in an environment underpinned by significant global regulation.

## The reality check: Generative AI implementation is underway — but far from mature

Despite the growing excitement around generative AI, only a small fraction of healthcare and MedTech organizations have realized its competitive advantage. A recent McKinsey & Company survey of over 100 industry leaders revealed that just 5% have captured measurable value from generative AI, while 49% are in various stages of scaling, and 45% remain in exploratory or early deployment phases. Meanwhile, investment is accelerating: by 2025, 20% of life sciences companies are expected to allocate over $10 million to generative AI initiatives. The promise? A potential $1 trillion in industry-wide improvements — from streamlined care delivery to enhanced clinical productivity (McKinsey & Company, 2022).

## Legacy systems: The silent barrier

Many QA/RA teams operate within fragmented digital ecosystems — often the result of mergers, acquisitions, and/or constrained budgets. These legacy systems, some dating back to the dot-com era, rely heavily on paper-based processes, siloed data, and point solutions that targeted the remediation of a historic priority issue. Without modernization of these legacy systems and the implementation of company-wide data literacy programs, AI cannot be effectively deployed. The first step in preparing the way is harmonizing data and processes across disparate platforms.

## Generative AI: Powerful, but not plug-and-play

AI tools must comply with global regulatory frameworks like US 21 CFR, ISO 13485, the EU AI Act, and EU GDPR. They must also be cost-effective and interoperable. For QA/RA leaders, this means evaluating the current digital landscape before introducing AI. A patchwork of document management systems — some still manual — requires strategic alignment before digitization can begin.

Moreover, generative AI carries risks. “Hallucinations” — false or misleading outputs — can compromise QA/RA processes such as regulatory submissions and damage reputations and trust with regulators and customers alike. A human-in-the-loop approach is essential to safeguard the quality and accuracy of QMS and RIM activities. This is where the expertise of QA/RA professionals remains critical to ensure the integrity of company systems.

## Privacy and security: Non-negotiables

AI implementation must be paired with robust privacy protocols. Protecting sensitive patient and organizational data is paramount, especially when AI is embedded in QMS and RIM workflows. Security must be built into the foundation — not retrofitted after deployment.

## Digital transformation: The bedrock of AI success

High-quality data is the lifeblood of effective AI. Integrating QMS with Product Lifecycle Management (PLM) and Enterprise Resource Planning (ERP) systems enables seamless data flow, breaks down silos, and fosters cross-functional collaboration. This is especially critical for predictive analytics, automated quality controls, and mandatory global compliance.

Integrated AI systems also offer scalability and flexibility, allowing MedTech organizations to adapt to shifting regulatory landscapes and market demands. The result? Streamlined workflows, improved product quality, and data-driven decision-making that drives a focus on product performance and patient safety.

## Data literacy: Empowering the workforce

A digitally literate workforce is essential. Data literacy programs help teams interpret and apply information effectively, driving transparency and informed decision-making. For QA/RA professionals, this supports the shift from reactive compliance to proactive quality leadership.

Data literacy programs also unify data streams across divisions, replacing fragmentation with cohesion. This enables the deployment of pragmatic AI tools that enhance process efficiency and elevate product quality — ultimately supporting better patient outcomes.

## Overcoming infrastructure challenges

To unlock AI's full potential, organizations must confront the limitations of legacy systems head-on. Automating administrative tasks and surfacing actionable insights allows QA/RA teams to focus on strategic, scientific, and value-added activities. With AI-enabled activities, and empowered as 'human-in-the-loop' QA/RA professionals, they can elevate enterprise-wide quality and regulatory performance while reinforcing patient safety, improving product quality, and supporting commercial success.

## Conclusion

For QA/RA leaders in MedTech, AI is not just a tool — it's a transformation. But success depends on readiness. By investing in digital infrastructure, fostering data literacy, and embedding privacy and compliance into every layer, organizations can build a resilient foundation for AI — and position themselves at the forefront of healthcare innovation.

1: McKinsey & Company. (2022, September 8). The gathering storm in U.S. healthcare. Retrieved from https://www.mckinsey.com/industries/healthcare/our-insights/the-gathering-storm-in-us-healthcare

**MICHAEL KING**
Senior Director, Product & Strategy, IQVIA

With over 20 years of experience leading global teams in quality assurance and regulatory affairs, Mike King, as Senior Director of Product and Strategy at IQVIA, ensures healthcare solutions meet complex global regulations and oversees platforms like SmartSolve® eQMS and RIM Smart to streamline quality and regulatory compliance processes.

IQVIA TECHNOLOGIES

**CONTACT US**
**iqvia.com/smartsolve**